Double-blind randomized treatment of poststroke depression using nefiracetam

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Stroke survivors frequently experience major depression.
• Nefiracetam, a gamma-aminobutyric acid (GABA) derivative, has shown preliminary promise in enhancing cerebral blood flow and mood.
• Previous research suggested potential benefits of nefiracetam for post-stroke mood disturbances.

Purpose of the Study:

• To evaluate the efficacy of nefiracetam compared to placebo in treating major depression in patients following a stroke.
• To determine if nefiracetam offers a significant therapeutic advantage over placebo for poststroke depression.

Main Methods:

• A double-blind, placebo-controlled trial involving 159 patients diagnosed with poststroke major depression within three months of stroke onset.
• Patients received either nefiracetam or a placebo.
• Statistical analysis using repeated measures analysis of covariance was employed to assess treatment effects over time.

Main Results:

• No significant time-by-treatment interaction was found, indicating nefiracetam did not generally outperform placebo across the study population.
• Overall response rates exceeded 70% and remission rates surpassed 40% in both the nefiracetam and placebo groups.
• A significant effect favoring nefiracetam was observed in the subgroup with the highest initial Hamilton Depression Rating Scale scores (most severe depression) at a 900 mg dose compared to 600 mg or placebo.

Conclusions:

• Nefiracetam was not found to be an effective standalone treatment for the general population of patients with poststroke depression.
• The study suggests a potential benefit of nefiracetam in improving symptoms for the most severely depressed patients following a stroke.